A New Obesity Pill May Burn Fat Without Suppressing Appetite

Injected GLP -1 drugs are incredibly effective in encouraging weight loss, they also bring some downside. Gastrointestinal side effects and muscle mass may decrease. Drugs are also expensive, insurance is $ 1000 or more a month in the United States before. Drug companies are interested in developing anti-oibitis pills due to their relatively cheap expenditure than injected and some patients will prefer to take a pill.

“There is still an unmeat clinical need, and there is a need to help Eolo,” Maria Pia said the CEO of the Pia Garat Company.

Iolo did not travel to make a weight-hurry pill. Researchers at the company were mainly trying to develop a drug to target inflammation, especially in obesity and type 2 diabetes. But when they start experimenting their experimental drugs in rats, it not only improves inflammation but also reduces body weight while in a high fat diet. They have been experimenting for up to nine months and they have found that rats have finally dropped to their early weight, even they were still eating the same, high-fat diet.

In rats, Sana also stored fat muscle mass. MRI scans show that rats treated with Sanna were more percent of thinner body mass than control despite sufficient fat decreasing.

“Before trying to increase our calorie outputs, we had the stimulus before,” Haclandak University Medical Center’s Center for Weight reduced and metabolic health co-director Hans Schmit, who was not involved in the study.

One of these is the drug combination phenfluramine-fentermine, known as phen-fen, which was sold for weight loss in the sixties but was removed from the market to cause heart loss. “They work on the overall metabolism they make you a jolt, this makes you encourage you this is especially working on the cellular level of your fat cells,” he said.

Of course, the study of Eolo was very small and the drug needs to be tested in more people to understand its effects better. The company is planning a second phase of trial at the end of this year that will include about 100 participants with obesity and will follow them for 12 weeks. They expect to conduct this trial in the United States. Garat thinks that the drug can be used to produce more weight loss as a stand -a procedure in the end or with GLP -1 drug.

“At this point we are bringing a backho to the construction site when we need more tools. We need more processes that work on the paths other than hunger,” Angella Fich, a primary care agency and Chief Medical Officer, said in obesity care. Fitch is not involved with Eolo.

Current GLP -1S can achieve 20 percent weight loss and it may be sufficient for some patients, others still have to lose more healthy weight. “New drugs,” he said, “Present the opportunity to make more impact.”